- $1.23m
- -$8.23m
- $0.67m
- 36
- 56
- 36
- 39
Annual cashflow statement for Vyant Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.21 | -6.88 | -8 | -40.9 | -22.7 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -12.1 | -0.801 | 2.29 | 26 | 7.6 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.99 | -1.59 | -0.284 | -2.69 | 0.891 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -12.6 | -8.66 | -5.37 | -17 | -13.7 |
| Capital Expenditures | -0.017 | -0.028 | -0.039 | -0.535 | -0.617 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.1 | 9.12 | 1.05 | 30.2 | 3.88 |
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1.08 | 9.09 | 1.01 | 29.6 | 3.26 |
| Financing Cash Flow Items | -0.31 | -1.01 | — | -0.032 | -0.036 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.15 | 3.31 | 2.64 | 7.19 | -0.149 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.38 | 3.72 | -1.79 | 19.8 | -10.6 |